Skip to main content

Share story

AI Infrastructure

NVIDIA Reportedly Building 'NemoClaw' Enterprise AI Agent Platform

NVIDIA Reportedly Building 'NemoClaw' Enterprise AI Agent Platform Image: Primary
NVIDIA is developing an enterprise AI agent platform called NemoClaw, according to sources cited by WIRED and reported by The Next Web. The company has been pitching the platform to major enterprise software players including Salesforce, Cisco, Google, Adobe, and CrowdStrike ahead of CEO Jensen Huang's upcoming keynote address. NemoClaw would extend NVIDIA's dominance from AI hardware into the software layer that enterprises use to deploy AI agents. The move represents a significant strategic expansion. NVIDIA has spent years establishing itself as the essential hardware provider for AI training and inference. An enterprise agent platform would give the company a stake in how businesses actually deploy AI workers. not just the chips they run on. The timing aligns with a broader industry push toward agentic AI, where software agents perform complex, multi-step tasks autonomously. If NVIDIA can position NemoClaw as the standard platform for building and running these agents, it would create a new recurring revenue stream alongside its GPU sales. Details on pricing, availability, and technical specifications have not been disclosed publicly.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from The Next Web and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Infrastructure
AI Infrastructure

Goldman and Apollo discuss selling portions of SpaceX chip financing

Goldman Sachs and Apollo Global Management are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX, Bloomberg reported. The discussions concern portions of the financing rather than a completed sale.

AI Capital
AI Capital

Isomorphic Labs seeks roughly $5 billion in funding talks

Alphabet's Isomorphic Labs is in talks to raise roughly $5 billion to support its use of artificial intelligence for drug discovery, Bloomberg reported, citing people familiar with the matter. The financing remains under discussion rather than a completed fundraising.